A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination
oleh: Sarah E. Greene, Yuefang Huang, Wooseob Kim, Mariel J. Liebeskind, Vinay Chandrasekaran, Zhuoming Liu, Parakkal Deepak, Michael A. Paley, Daphne Lew, Monica Yang, Mehrdad Matloubian, Lianne S. Gensler, Mary C. Nakamura, Jane A. O'Hallaran, Rachel M. Presti, Sean P.J. Whelan, William J. Buchser, Alfred H.J. Kim, Gary J. Weil
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2023-02-01 |
Deskripsi
Objective: Lateral flow assays (LFA) are sensitive for detecting antibodies to SARS-CoV-2 proteins within weeks after infection. This study tested samples from immunocompetent adults, and those receiving treatments for chronic inflammatory diseases (CID), before and after mRNA SARS-CoV-2 vaccination. Methods: We compared results obtained with the COVIBLOCK Covid-19 LFA to those obtained by anti-spike (S) ELISA. Results: The LFA detected anti-S antibodies in 29 of 29 (100%) of the immunocompetent and 110 of 126 (87.3%) of the CID participants after vaccination. Semiquantitative LFA scores were statistically significantly lower in samples from immunosuppressed participants, and were significantly correlated with anti-S antibody levels measured by ELISA. Conclusions: This simple LFA test is a practical alternative to laboratory-based assays for detecting anti-S antibodies after infection or vaccination. This type of test may be most useful for testing people in outpatient or resource-limited settings.